Cyclerion Therapeutics (CYCN) EBITDA Margin (2019 - 2025)
Cyclerion Therapeutics (CYCN) recorded quarterly EBITDA Margin of 111.54% in Q3 2025, up 93.8% quarter-over-quarter from 1797.85% in Q2 2025, and up 26114.0% on a YoY basis from N/an in Q3 2024.
Cyclerion Therapeutics (CYCN) EBITDA Margin (2019 - 2025) Analysis & Trends
Cyclerion Therapeutics' EBITDA Margin history runs 6 years deep, the most recent figure standing at 111.54% for Q3 2025.
- In Q3 2025, EBITDA Margin rose 26114.0% year-over-year to 111.54%; the TTM figure through Sep 2025 stood at 125.22% (up 265210.0% YoY), while the FY2024 annual figure was 181.4%, changed N/A from the prior year.
- EBITDA Margin was 111.54% for Q3 2025 at Cyclerion Therapeutics, up from 1797.85% in the prior quarter.
- In the past five years, EBITDA Margin ranged from a high of 27.8% in Q4 2024 to a low of 21611.29% in Q1 2021.
- Historically, EBITDA Margin has averaged 3483.51% across 4 years, with a median of 1797.85% in 2025.
- The sharpest annual moves came in 2021 and 2022: EBITDA Margin plunged 1961662 bps in 2021, then surged 1978597 bps in 2022.
- A 4-year view of EBITDA Margin shows it stood at 2690.06% in 2021, then tumbled by 63 bps to 4389.87% in 2022, then soared by 101 bps to 27.8% in 2024, then plunged by 501 bps to 111.54% in 2025.
- The last three EBITDA Margin figures came in at 111.54% (Q3 2025), 1797.85% (Q2 2025), and 1764.2% (Q1 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 719,706.53 Bn | 719,706.50 Bn | - | - |
| 2 | Belite Bio | 55,800.00 Bn | 55,800.00 Bn | - | - |
| 3 | Quantum Biopharma | 18,182.30 Bn | 18,182.29 Bn | - | - |
| 4 | Legend Biotech | 3,154.00 Bn | 3,153.71 Bn | 242.10 Mn | -6.43% |
| 5 | Akari Therapeutics | 1,844.30 Bn | 1,844.29 Bn | - | - |
| 6 | Evaxion A | 1,567.96 Bn | 1,567.94 Bn | - | - |
| 7 | Psyence Biomedical | 251.43 Bn | 251.42 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 112.56 Bn | 105.31 Bn | 2.59 Bn | 38.10% |
| 9 | Abivax | 94.37 Bn | 94.37 Bn | - | - |
| 10 | Cyclerion Therapeutics | 11.50 Mn | 8.26 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2025 | -111.54% |
| Jun 30, 2025 | -1,797.85% |
| Mar 31, 2025 | -1,764.20% |
| Dec 31, 2024 | 27.80% |
| Sep 30, 2024 | -372.68% |
| Jun 30, 2022 | -4,389.87% |
| Mar 31, 2022 | -1,825.32% |
| Dec 31, 2021 | -2,690.06% |
| Sep 30, 2021 | -3,244.25% |
| Jun 30, 2021 | -539.37% |
| Mar 31, 2021 | -21,611.29% |
| Dec 31, 2020 | -14,457.14% |
| Sep 30, 2020 | -4,702.25% |
| Jun 30, 2020 | -2,609.61% |
| Mar 31, 2020 | -1,994.67% |
| Dec 31, 2019 | -1,760.70% |
| Sep 30, 2019 | -1,953.65% |
| Jun 30, 2019 | -1,981.45% |